Despite the widespread use of drug-eluting stent technology, arterial restenosis remains an important complication following percutaneous revascularization procedures [1] . Viewed simply, it can be considered as a disproportionate reparative reaction to iatrogenic vascular injury, that is brought about by a complex process, underpinned by different molecular pathways and contributions from diverse cell types recruited to the vessel wall or resident locally within its mural layers [2] . Central pathophysiological factors comprise the dysregulated deposition and metabolism of extracellular matrix components, along with alterations in cellular proliferation, migration and transdifferentiation. These ultimately lead to excessive neointima formation and re-narrowing of the arterial lumen. Although its frequency has declined in recent years, the residual risk of restenosis after percutaneous and surgical revascularization has prompted ongoing evaluation of experimental strategies to prevent or treat its progression, including the administration of different progenitor cell types to facilitate normal arterial healing and avert aberrant, deleterious repair [3] [4] [5] [6] [7] .
In general terms, the influence of progenitor cells on vascular health cannot be broadly summarized as adaptive or maladaptive, as it is dependent on both specific cell type and disease context. This is underscored by contrasting outcomes following the delivery of "endothelial progenitor cells" (EPCs) or smooth muscle progenitor cells in different small animal models of spontaneous atherosclerosis, vascular graft arteriopathy or vascular injury (wire or balloon) [8] . While there is cautionary evidence to suggest that systemic infusion of EPCs may accentuate atherosclerotic burden in ApoE-deficient mice and prime atheroma toward an inflammation-rich state [9] , these cells have also been used to beneficial effect to modulate vascular remodeling after intimal disruption [10] . After arterial angioplasty and stenting, it is desirable to accelerate intimal re-endothelialization in order to limit inflammation and extracellular matrix deposition within the vessel wall and in turn avoid the development of neointimal hyperplasia and in-stent restenosis. Therefore infusions of pro-angiogenic or endothelial progenitor cells from different tissue sources (e.g. bone marrow [BM] , blood, adipose) have been used in preclinical studies to promote rapid luminal endothelial recovery after vascular insult [5, 11, 12] . Others have also attempted to achieve this by designing vascular stents and grafts that readily attract EPC coverage through magnetic forces [13, 14] or by special coating with capture antibodies [15] .
Beyond interest in the application of different EPC subsets, there has also been increasing recognition that mesenchymal stromal cells (MSCs) from BM or other tissue sources may be well-suited to confer reparative benefits in the setting of vascular wall injury [2] . Owing to their ease of isolation and ex vivo expansion, potential for allogeneic, "off-the-shelf" use and range of pro-angiogenic andmyogenic properties, these cells have been extensively investigated for their utility in cardiovascular therapeutics [16] , with favorable results after their delivery in ischemic [17, 18] and nonischemic myocardial disease [19] . In the setting of arterial repair and attenuation of restenosis after vascular insult, there has been some conjecture as to the beneficial potential of MSCs. Theoretical concern has been raised that these cells may have a pro-fibrotic effect on the vessel wall and that their ability to promote angiogenesis (e.g. through secretion of vascular endothelial growth factor
[VEGF] and other cytokines) could contribute to deleterious expansion of adventitial vasa vasorum [2] . In one study that investigated intravenous delivery of MSCs seven days after femoral artery wire injury, injected cells were found to adhere readily to sites of endothelial disruption, ultimately contributing to the cellular composition of neointimal hyperplasia, with some indication for their smooth muscle cell transformation [4] . However for the most part, the weight of preclinical evidence in vascular injury models has supported the capacity of MSCs to facilitate early endothelial repair, modulate local inflammatory responses and reduce late smooth muscle cell proliferation and neointimal thickening [2] .
To this end, Forte et al. have previously reported that systemic infusion of allogeneic BM MSCs resulted in attenuation of inward remodeling and luminal narrowing thirty days into a rodent model of carotid artery crush and arteriotomy [3] . This surgical model has the important distinction from wire or balloon injury in that it creates a greater degree of arterial wall trauma by disrupting both the internal and external elastic lamina. In this initial study, DiI-labeled MSCs were found to home to the injured arterial wall, progressively accumulating within the adventitia, perivascular tissue and to a lesser extent the media and intima, over the first week after delivery. This was accompanied by early modulation of different cytokines within the injured vessel, but not the contralateral, unaffected artery to which cells did not track. In particular, there was (1) an increase in the local expression of the immunosuppressive factor TGF-β, which may have anti-proliferative effects on smooth muscle cells and influence the differentiation of adventitial myofibroblasts, along with (2) reductions of the pro-inflammatory cytokines IL-1β and MCP-1, which may limit macrophage invasion in the healing arterial wall.
In the current issue of Cardiovascular Drugs and Therapy, the same authors further show that early after their delivery, MSCs induce pleiotropic effects on other inflammatory and angiogenic mediators that are also implicated in vascular healing and response to injury [20] . They describe an initial spike at day 3 in mRNA expression of VEGF in carotid arteries from cell-treated rats compared to those that received control medium, and a reduction in mRNA levels of Toll-like receptors (TLR) 2 and 4 that persisted until at least day 7. Furthermore serum levels of VEGF were also increased after cell transfer, while there were diminished titers of a range of soluble inflammation-related molecules (CXCL1, ICAM-1, L-Selectin, LIX/CXCL5, CCL5/ RANTES), as well as TIMP-1, which has complex actions on extracellular matrix remodeling, cell growth and death. Interestingly, MSC infusion was not found to impact on immunohistochemical measures of local oxidative stress or apoptosis in the injured vessels, but it was accompanied by a substantial increase in the presence of proliferating cells throughout the vessel wall, as determined by incorporation of BRDU. Almost universally, MSC-induced changes were more prominent at day 3 than day 7, while later time-points were not assessed to determine the durability of cell effect. Forte et al. did not directly investigate how these alterations in different soluble mediators impacted on specific cellular and extracellular targets within the arterial wall, nor did they determine whether the vascular homing of MSCs constituted actual engraftment and differentiation into endothelial or smooth muscle cell subtypes. However, they surmise that MSCs are likely to exert immunomodulatory effects on different innate and adoptive inflammatory cell subtypes that are activated after arterial injury, a finding that is consistent with recent results from another study [21] .
The paracrine and trophic properties of MSCs are well appreciated and have been given increasingly more mechanistic weight in terms of mediating tissue repair than the capacity of MSCs to undergo adoptive transdifferentiation [16] . In the case of postnatal arteries, recent discoveries have identified the presence of diverse progenitor cell populations resident throughout the different mural layers [8] . Local progenitor cells may provide an important early target for the paracrine influence of exogenous MSC transfer, in keeping with Forte et al.'s observation that cell delivery triggered an increase in proliferating cells within the vessel wall. Pro-mitogenic stimulation of intimal EPCs could theoretically help to initiate arterial endothelialization and in turn contribute to the ability of MSCs to mitigate restenosis, as reported in their previous study [3] .
Overall, the major implication of Forte et al.'s studies is that MSC therapy may trigger important cues to reset the cascade of inflammatory signals that are activated in the initial stages of vascular healing and to prime other cell populations that participate in local arterial repair. This work complements the growing preclinical experience acquired with EPC transfer in animal models of vascular injury and broadens the therapeutic scope of MSCs, which have considerable clinical appeal because of their possible allogeneic application. It also provides a framework to develop strategies to optimize the vascular reparative properties of MSCs. These may include combining MSC delivery with other cell types [4] , or augmenting the paracrine capacity of MSCs through techniques such as immunoselective enrichment [22] , hypoxic or pharmacological preconditioning or genetic transfection. The latter approach recently has been used to enhance the ability of EPCs to inhibit neointima formation [23, 24] .
Although recent data indicate that intravenous injection of MSCs may be safely tolerated [18] , it is likely that their effectiveness could be further improved by directing cells more specifically to the actual site of arterial injury or revascularization. This could be achieved by direct infusion into the lumen of the target vessel, or by using novel approaches like magnetic tagging [25] , ultrasound-generated acoustic radiation forces [26] or antibody capture to attract cells to the surface of the revascularized conduit (stent or graft). New catheter injection systems are also in development that will enable cells to be injected transluminally into the vascular adventitia and periadventitial space. Given the promising results from small animal experiments, it is highly probable that the investigation of MSC therapy will quickly progress to large animal and human studies of arterial injury, revascularization and restenosis in the near future.
